Literature DB >> 30385249

Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma.

Li-Hua Jiang1, Ying-Li Hao2, Jing-Wei Zhu3.   

Abstract

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with several genomic alterations, while the viral-chemical etiology along with molecular mechanisms of HCC pathogenesis remains largely unknown. This study aimed to determine expression profile and prognostic value of HER-2/neu, STAT3 and SOCS3 in HCC.
METHODS: Immunohistochemistry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were performed to evaluate the expression of HER-2/neu, STAT3 and SOCS3 in HCC tissues and adjacent normal tissues collected from 176 HCC patients.
RESULTS: HER-2/neu and STAT3 levels were higher and SOCS3 expression was lower in HCC tissues than in adjacent normal tissues. HER-2/neu, STAT3 and SOCS3 levels were associated with histological grade, tumor diameter, TNM stage, vascular invasion, lymph node metastasis and distant metastasis in HCC. SOCS3 expression was negatively associated with HER-2/neu and STAT3 expression. HCC patients with higher HER-2/neu and STAT3 levels had shorter overall, disease-free and disease-specific survival, whereas the opposite was found in patients with higher SOCS3 expression. In Cox regression analysis, tumor size, TNM stage, and STAT3 expression were identified as independent prognostic factors of HCC.
CONCLUSION: Taken together, these observations suggest that HER-2/neu, STAT3 and, SOCS3 are related to the aggressive tumor behavior and STAT3 has potential value as a prognostic factor for HCC.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Human epidermal growth factor receptor-2; Primary hepatocellular carcinoma; Prognosis; Signal transducer and activator of transcription 3; Suppressor of cytokine signaling 3

Mesh:

Substances:

Year:  2018        PMID: 30385249     DOI: 10.1016/j.clinre.2018.09.011

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  4 in total

1.  ROS‑mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC.

Authors:  Xiang Cao; Xin-Ming Chen; Wei-Zhang Xiao; Ben Li; Bo Zhang; Qiong Wu; Qun Xue
Journal:  Int J Mol Med       Date:  2020-12-15       Impact factor: 4.101

2.  Prognostic Significance of SOCS3 in Patients With Solid Tumors: A Meta-Analysis.

Authors:  Xia Zheng; Jie Shao; Sihui Wei; Yu Gu; Jun Qian
Journal:  Front Surg       Date:  2022-02-28

3.  NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.

Authors:  SiZhe Yu; Yu Wang; KeJia Lv; Jia Hou; WenYuan Li; Xiao Wang; Hui Guo; WenJuan Wang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

4.  EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling.

Authors:  Ze-Kun Liu; Can Li; Ren-Yu Zhang; Ding Wei; Yu-Kui Shang; Yu-Le Yong; Ling-Min Kong; Nai-Shan Zheng; Ke Liu; Meng Lu; Man Liu; Cai-Xia Hu; Xiao-Zhen Yang; Zhi-Nan Chen; Huijie Bian
Journal:  Mol Cancer       Date:  2021-05-27       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.